NEW YORK— Diagnostics startup Plexision aims to cut down delays in testing for organ transplant rejection with an antigen-based blood test for early signs a patient's immune system is attacking the donated tissue.

Plexision, a biotechnology company, which provides personalized diagnostic testing services for organ transplant patients has completed development of a six-hour blood test to predict organ transplant rejection - PlexAPR^TM.

Plexision, a US-based biotechnology company, has initiated overseas operations with the establishment of a reference laboratory in Hyderabad, India.

Plexision, a biotechnology company, is offering the first blood test panel capable of reporting the risk of cytomegalovirus infection and transplant rejection within six hours after samples arrive at its reference laboratory.